35975-57-6

Usage

Uses

Used in Pharmaceutical Research and Development:
ETHYL 8-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLATE is used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and organic compounds, leveraging its potential biological activities for medicinal applications.
Used in Organic Synthesis:
In the field of organic chemistry, ETHYL 8-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLATE is utilized as a key component in the synthesis of complex organic compounds, contributing to the development of new chemical entities.
Used in Antimicrobial Applications:
ETHYL 8-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLATE is used as an antimicrobial agent, exhibiting properties that can combat various types of microorganisms, thereby serving as a potential candidate for the development of new antimicrobial drugs.
Used in Antitumor Applications:
In oncology, ETHYL 8-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLATE is used as an antitumor agent, showing promise in the treatment of cancer due to its potential to interfere with tumor growth and progression mechanisms.
Used in Anti-inflammatory Applications:
ETHYL 8-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLATE is used as an anti-inflammatory agent, indicating its potential to reduce inflammation, which is a common therapeutic target in various diseases and conditions.
Used in Different Industries:
ETHYL 8-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLATE's applications span across various industries, including pharmaceuticals, agriculture, and chemical manufacturing, where it serves as a crucial intermediate for the development of new products and compounds.

InChI:InChI=1/C12H10BrNO3/c1-2-17-12(16)8-6-14-10-7(11(8)15)4-3-5-9(10)13/h3-6H,2H2,1H3,(H,14,15)

Upstream product

• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 615-36-1 2-bromoaniline 
• 35975-63-4 2-[(2-bromo-phenylamino)methylene]malonic acid diethyl ester 
• 40516-46-9 diethyl (ethoxymethylene)malonate 

Downstream Products

• 206258-97-1 ethyl 4-chloro-8-bromo-3-quinolinecarboxylate 
• 347146-14-9 ethyl 8-bromoquinoline-3-carboxylate 
• 1449736-79-1 N⁴-(4-methoxybenzyl)-N⁸-(3-(trifluoromethyl)phenyl)quinoline-4,8-diamine 
• 1449736-78-0 N⁸-(3-(trifluoromethyl)phenyl)quinoline-4,8-diamine 
• 1449735-97-0 2-chloro-5-(pivalamidomethyl)-N-(8-((3-(trifluoromethyl)phenyl)amino)quinolin-4-yl)benzamide 

Relevant academic research and scientific papers

3-(Benzo[: D] thiazol-2-yl)-4-aminoquinoline derivatives as novel scaffold topoisomerase i inhibitor via DNA intercalation: Design, synthesis, and antitumor activities

Twenty-seven 3-(benzo[d]thiazol-2-yl)-4-aminoquinoline derivatives have been designed and synthesized as topoisomerase I inhibitors. The in vitro anti-proliferation evaluation against four human cancer cell lines (MGC-803, HepG-2, T24, and NCI-H460) and one normal cell line (HL-7702) indicated that most of them exhibited potent cytotoxicity. Among them, 5a was identified as the most promising candidate with a low IC50 value of about 2.20 ± 0.14 and was selected for further exploration. Spectroscopic analyses and agarose-gel electrophoresis assays indicated that 5a could interact with DNA and strongly inhibit topoisomerase I (Topo I). Further screening of the Topo I activity of compounds 5b, 5c, 5e, 5f, 5h, 5i, 5j, 5l, and 5n suggested that some of the compounds might exert quite a different cytotoxicity profile to that of 5a. Molecular modeling studies confirmed that 5a adopts a unique mode to interact with DNA and Topo I. Other molecular mechanistic studies suggested that the treatment of MGC-803 cells with 5a induces S phase arrest, up-regulates the pro-apoptotic protein, down-regulates the anti-apoptotic protein, activates caspase-3, and subsequently induces mitochondrial dysfunction so as to induce cell apoptosis. The in vivo efficiency of 5a was also evaluated on MGC-803 xenograft nude mice and the relative tumor growth inhibition was 42.4percent at 12 mg kg-1 without an obvious loss in the body weight. This journal is

BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES

The present invention provides compounds of formula (I): which are useful in the control of endoparasites, for example heartworms, in warm-blooded animals.

Discovery of 4-Aminoquinoline-3-carboxamide derivatives as potent reversible Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, 25, displayed a stronger inhibitory effect on both BTKWT (IC50 = 5.3 nM) and BTKC481S (IC50 = 39 nM). In a rodent collagen-induced arthritis model, compound 25 efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases.

QUINOLINE DERIVATIVES FOR TREATING INFECTIONS WITH HELMINTHS

The present invention covers quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate c

PROCESS FOR PREPARING ANTIHELMINTIC 4-AMINO-QUINOLINE-3-CARBOXAMIDE DERIVATIVES

The present invention relates to a new process for preparing quinoline compounds of the general formula (II): in which Q, A, R4, R3 and R3',are as defined herein, as well as to the intermediate compounds of said new process.

Micromolecular reversible BTK inhibitor for treating rheumatoid arthritis

The invention relates to a micromolecular reversible BTK inhibitor for treating rheumatoid arthritis, and specifically provides a compound. The compound is the compound as shown in a formula I, or a stereisomer, a geometrical isomer and a tautomer thereof, nitric oxide, aquo-complex, a solvate, a metabolite and pharmaceutically acceptable salts and prodrugs. The inventor finds that polysubstitutedquinolone compound or derivate thereof as shown in formula I can be used as the BTK inhibitor and is high in activity during treating rheumatoid arthritis.

A four-ring quinolinone alkaloid derivative and its preparation method and application (by machine translation)

The invention relates to a four-ring quinolinone alkaloid derivative, or a tautomer thereof, stereo isomer, racemate, enantiomer of non-isometric mixture, geometric isomer, solvate, pharmaceutically acceptable salt or prodrug, and pharmaceutical composition containing the compound. The invention also discloses such compounds and pharmaceutical compositions thereof as a medicament, in particular as anti-virus, antibacterial and the anti-parasitic drug use. (by machine translation)

Photoreductive Removal of O-Benzyl Groups from Oxyarene N-Heterocycles Assisted by O-Pyridine-pyridone Tautomerism

Facile photoreductive protocols have been developed to remove benzyl O-protective groups from oxyarene N-heterocycles at positions capable for 2-/4-O-pyridine-2-/4-pyridone tautomerism. Blue light irradiation, a [Ru] or [Ir] photocatalyst, and ascorbic acid in a water-acetonitrile solution debenzylates a variety of aryl N-heterocycles cleanly and selectively. Ascorbic acid has two functions in the reaction. On the one hand, it protonates the N-heterocycles that reduces their reduction potentials notably and on the other hand it acts as a sacrificial reductant. Reduction potentials and free energy barriers calculated at the CPCM-B3LYP/6-31+G? level can predict the reactivities of the studied substrates.

QUINOLINE DERIVATIVES AS SMO INHIBITORS

Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.

BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.